The Thailand Public Health Ministry is monitoring the spread of Clade I mpox to North America following confirmation of the first case in the U.S. state of Connecticut, a development that underscores the need for travelers and residents in Thailand to remain vigilant as global movement resumes ahead of peak travel season.
Why This Matters
• Travel-linked transmission: The Connecticut patient had recently visited Western Europe, a region experiencing active Clade I outbreaks. Thailand sees heavy traffic from both Europe and the U.S.
• Vaccine availability: The JYNNEOS vaccine remains the most effective preventive measure, requiring a two-dose series for full protection.
• Risk profile: Gay and bisexual men, and others who have sex with men, face disproportionate risk and should prioritize vaccination before summer travel.
• Low but rising caseload: Over 20 Clade I cases have been confirmed in the U.S., most tied to international travel or close contact with travelers.
What the Connecticut Case Reveals
The Connecticut Department of Public Health confirmed the state's first Clade I mpox infection through testing at the State Public Health Laboratory. The individual contracted the virus after traveling to Western Europe, where Clade I is circulating alongside endemic cases in Central and Eastern Africa. Health officials emphasized the case poses no immediate threat to the broader public, given mpox's reliance on sustained close contact for transmission.
Clade I mpox, historically confined to the Democratic Republic of Congo and neighboring countries, has migrated beyond Africa for the first time in a sustained manner. Since late 2023, the strain has appeared sporadically in Europe, with travel-associated cases now documented across multiple U.S. states, including California, New York, and now Connecticut.
Understanding Clade I: Severity and Symptoms
Clade I mpox has historically carried a case fatality rate of 5–10%, significantly higher than the Clade II strain (0.1–3.6%) that drove the 2022 global outbreak. However, recent data from high-income countries with robust healthcare systems suggest the mortality rate for Clade I can drop to below 1% when patients receive prompt supportive care and medical intervention.
The virus manifests through a distinctive progression: an initial prodromal phase marked by fever above 38.5°C, headache, muscle aches, fatigue, sore throat, and swollen lymph nodes—particularly in the neck, armpits, or groin. Within 1 to 21 days after exposure, a characteristic rash emerges, evolving through four stages: flat spots (macules), raised bumps (papules), fluid-filled vesicles, and pus-filled pustules. The lesions are deeply embedded, firm, and often feature a central depression (umbilication). They can appear on the face, palms, soles, genitals, and anus.
Severe complications remain a risk for immunocompromised individuals, including people living with HIV who have low CD4 counts, children, and pregnant women. These groups face heightened danger of widespread skin lesions, dehydration, secondary bacterial infections, and encephalitis.
Transmission Dynamics and Community Spread
Mpox spreads through prolonged skin-to-skin contact with rashes, scabs, or bodily fluids from an infected person. Sexual contact has emerged as a key transmission route, particularly for Clade I subclade Ib, which is driving the current Western European and U.S. clusters. The virus can also spread via contaminated fomites—bedding, towels, clothing—that have touched infectious lesions.
A person remains contagious from four days before symptoms appear until all scabs have fallen off and fresh skin has formed underneath. While the incubation period typically ranges from 3 to 17 days, infected individuals are usually not contagious during this asymptomatic window.
Notably, community transmission cases have emerged in the U.S. with no recent international travel history, signaling that localized chains of transmission are possible, though still rare. Those patients were epidemiologically linked to earlier cases involving travelers, demonstrating how the virus can establish footholds beyond initial import events.
Global Context: Cases Reported Worldwide
Since the emergence of sustained international transmission in late 2023, confirmed Clade I mpox cases have been reported across Europe and North America, with the epicenter remaining Central and Eastern Africa. The U.S. Centers for Disease Control and Prevention (CDC) continues to monitor case numbers as summer travel intensifies and more travel-associated cases emerge.
Nearly all confirmed cases in the U.S. involve recent travel to outbreak zones in Africa or Europe, or close contact with travelers. The total caseload continues to rise, with most infections tied directly to international movement and high-risk contact patterns.
What This Means for Thailand Residents
For people living in Thailand, the Connecticut case serves as a reminder that mpox does not respect borders, and Thailand's position as a major travel hub heightens exposure risk. While Clade I remains rare in Southeast Asia, the following practical measures are advisable:
Vaccination: The JYNNEOS vaccine is effective against both Clade I and Clade II. Completing the full two-dose regimen is critical, particularly for gay and bisexual men, individuals with multiple sexual partners, and anyone planning travel to Europe or Africa. Check with the Thailand Ministry of Public Health or private clinics in Bangkok, Chiang Mai, and Phuket for vaccine availability.
Travel Precautions: Travelers returning from Western Europe, Central Africa, or Eastern Africa should monitor for symptoms for up to 21 days post-arrival. Avoid intimate skin-to-skin contact if you or a partner develop unexplained rashes, fever, or swollen lymph nodes.
Recognition and Response: Early identification is key. If you notice a firm, painful rash with a central dimple, especially following recent travel or sexual contact with a new partner, seek medical attention at a hospital with infectious disease expertise. Inform healthcare providers of your travel history immediately.
Low General Risk, High Stakes for Key Groups: The overall risk to the general Thai population remains low. However, the disproportionate impact on men who have sex with men—a pattern consistent with the 2022 Clade II outbreak—means targeted outreach and vaccine uptake in at-risk communities could prevent localized clusters.
Public Health Response and Availability
Health authorities have urged at-risk individuals to complete the JYNNEOS vaccine series, describing it as safe, effective, and widely accessible. The same vaccine stock used during the 2022 outbreak remains in circulation and is expected to confer cross-protection against Clade I.
Thailand's response to mpox has historically been proactive, with the Department of Disease Control coordinating surveillance, laboratory testing, and vaccine distribution during the 2022–2023 Clade II surge. Residents should verify whether their local health authority has updated guidance in light of Clade I's emergence in neighboring travel corridors.
The Bottom Line
Clade I mpox has arrived in the United States via travelers who visited Western Europe, part of a growing series of travel-associated cases documented in recent months. While the strain is more severe than the Clade II variant that circulated globally in 2022, mortality rates drop significantly with timely medical care—a reality that favors countries with strong healthcare infrastructure.
For Thailand residents, the lesson is clear: mpox is mobile, summer travel is ongoing, and vaccination is the single most effective countermeasure. Gay and bisexual men, frequent travelers, and anyone with recent exposure to symptomatic individuals should prioritize completing the two-dose JYNNEOS series now, before outbreak conditions worsen internationally. The virus thrives on close contact; public health systems thrive on early action.
